CSF3 and acute myeloid leukemia: GCSF may act as a sensitizer of leukemic cells to the chemotherapy in AML patients; clinical studies show that the presence of GCSF in FLAG regimens increases the rate of disease-free survival of patients due to its effect of priming the leukemic cells to the chemotherapy [37,38,39,40,41].